Get started
Standard BioTools Inc.Standard BioTools Inc.Standard BioTools Inc.

Standard BioTools Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

LAB chart


Full chart

LAB upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪677.51 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.71 USD
Net income (FY)
‪−74.66 M‬ USD
Revenue (FY)
‪106.34 M‬ USD
Shares float
‪360.25 M‬
Beta (1Y)
2.03

Employees


Employees (FY)
539
Change (1Y)
+16 +3.06%
Revenue / Employee (1Y)
‪197.29 K‬ USD
Net income / Employee (1Y)
‪−138.51 K‬ USD

About Standard BioTools Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Michael Egholm
Website
standardbio.com
Headquarters
South San Francisco
Founded
1999
FIGI
BBG000S8WQB6
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LAB news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

LAB highest yielding bonds


FLDM4094699
Standard BioTools Inc. 2.75% 01-FEB-2034
Yield to maturity
17.12%
Maturity date
Feb 1, 2034

Explore more bonds 

Frequently Asked Questions


The current price of LAB is 1.77 USD — it has decreased by −4.21% in the past 24 hours. Watch Standard BioTools Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Standard BioTools Inc. stocks are traded under the ticker LAB.
LAB stock has fallen by −6.19% compared to the previous week, the month change is a 5.81% rise, over the last year Standard BioTools Inc. has showed a −23.26% decrease.
We've gathered analysts' opinions on Standard BioTools Inc. future price: according to them, LAB price has a max estimate of 4.00 USD and a min estimate of 2.50 USD. Watch LAB chart and read a more detailed Standard BioTools Inc. stock forecast: see what analysts think of Standard BioTools Inc. and suggest that you do with its stocks.
LAB reached its all-time high on Feb 27, 2014 with the price of 49.46 USD, and its all-time low was 0.92 USD and was reached on Nov 9, 2022. View more price dynamics on LAB chart.
See other stocks reaching their highest and lowest prices.
LAB stock is 4.90% volatile and has beta coefficient of 2.03. Track Standard BioTools Inc. stock price on the chart and check out the list of the most volatile stocks — is Standard BioTools Inc. there?
Today Standard BioTools Inc. has the market capitalization of ‪677.51 M‬, it has decreased by −7.81% over the last week.
Yes, you can track Standard BioTools Inc. financials in yearly and quarterly reports right on TradingView.
Standard BioTools Inc. is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
LAB earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.09 USD resulting in a 22.22% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Standard BioTools Inc. earnings.
Standard BioTools Inc. revenue for the last quarter amounts to ‪44.97 M‬ USD, despite the estimated figure of ‪41.00 M‬ USD. In the next quarter, revenue is expected to reach ‪43.03 M‬ USD.
LAB net income for the last quarter is ‪−26.94 M‬ USD, while the quarter before that showed ‪−45.72 M‬ USD of net income which accounts for 41.08% change. Track more Standard BioTools Inc. financial stats to get the full picture.
No, LAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 539.00 employees. See our rating of the largest employees — is Standard BioTools Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Standard BioTools Inc. EBITDA is ‪−103.12 M‬ USD, and current EBITDA margin is −45.01%. See more stats in Standard BioTools Inc. financial statements.
Like other stocks, LAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Standard BioTools Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Standard BioTools Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Standard BioTools Inc. stock shows the strong sell signal. See more of Standard BioTools Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.